Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYD-TDV Schedules +/- Yellow Fever Vaccine
NCT01488890Phase 2Completed
- Sponsor
- Sanofi
- Start
- Dec 2011
- Primary completion
- Sep 2013
- Modality
- Live Attenuated Vaccines, Recombinant Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Cyd dengue virus serotype 1 live (attenuated) antigen in dengue fever (4 arms), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype and Percentage of Participants With Seropositivity Against Each Dengue Virus Serotype. Started Dec 2011; status: completed.
02
Drugs
Cyd dengue virus serotype 1 live (attenuated) antigen
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT01488890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01488890.